Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Saint Luke's Cancer Center - Allentown — Allentown, Pennsylvania
- Saint Luke's University Hospital-Bethlehem Campus — Bethlehem, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Pennsylvania: - Carlisle Regional Cancer Center — Carlisle, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
- UPMC Cancer Center at UPMC Horizon — Farrell, Pennsylvania
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus — Harrisburg, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Pennsylvania: - Research Site — Hershey, Pennsylvania
- Research Site — Philadelphia, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Wilkes-Barre, Pennsylvania
Phase 3 Recruiting Industry
The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…
Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Sites in Pennsylvania: - Penn-Medicine - Abramson Cancer Center University of Pennsylvania — Philadelphia, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Pennsylvania: - Honickman Center ( Site 5033) — Philadelphia, Pennsylvania
- Asplundh Cancer Pavilion ( Site 5002) — Willow Grove, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Pennsylvania: - Fox Chase Cancer Center — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center - Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…
Sponsor: AstraZeneca
NCT ID: NCT06079671
Sites in Pennsylvania: - Research Site — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…
Sponsor: SOFIE
NCT ID: NCT07217704
Sites in Pennsylvania: - University of Pennsylvania, Perelman School of Medicine — Philadelphia, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- Jefferson Torresdale Hospital — Philadelphia, Pennsylvania
- Asplundh Cancer Pavilion — Willow Grove, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in Pennsylvania: - UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
- Saint Vincent Hospital — Erie, Pennsylvania
- UPMC Cancer Center at UPMC Horizon — Farrell, Pennsylvania
- IRMC Cancer Center — Indiana, Pennsylvania
- Jefferson Hospital — Jefferson Hills, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Pennsylvania: - USOR Alliance Cancer Specialist — Doylestown, Pennsylvania
- Allegheny Health Network — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…
Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in Pennsylvania: - University of Pennsylvania — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Pennsylvania: - Avenzo Therapeutics Recruiting Site — Philadelphia, Pennsylvania
Phase 2 Recruiting Industry
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain a…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06769698
Sites in Pennsylvania: - Asplundh Cancer Pavilion — Willow Grove, Pennsylvania
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Pennsylvania: - Alliance Cancer Specialists — Horsham, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Pennsylvania: - University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Pennsylvania: - Cancer Care Associates of York (site 206) — York, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemip…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06980038
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 2 Recruiting Academic/Other
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06123338
Sites in Pennsylvania: - University of Pennsylvania (Data Collection Only) — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of partici…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06469944
Sites in Pennsylvania: - UPMC Hillman Cancer Center-UPMC ( Site 6904) — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
Sponsor: AstraZeneca
NCT ID: NCT06535607
Sites in Pennsylvania: - Research Site — Philadelphia, Pennsylvania
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
Phase 2 Recruiting Academic/Other
This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research s…
Sponsor: Massachusetts General Hospital
NCT ID: NCT05668962
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less …
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT06458036
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The pur…
Sponsor: Abramson Cancer Center at Penn Medicine
NCT ID: NCT05758688
Sites in Pennsylvania: - Lancaster General Health - Ann B. Barshinger Cancer Institute — Lancaster, Pennsylvania
- University of Pennsylvania — Philadelphia, Pennsylvania